Nothing Special   »   [go: up one dir, main page]

IL138738A0 - Substituted pyrrolidine hydroxamate metalloprotease inhibitors - Google Patents

Substituted pyrrolidine hydroxamate metalloprotease inhibitors

Info

Publication number
IL138738A0
IL138738A0 IL13873899A IL13873899A IL138738A0 IL 138738 A0 IL138738 A0 IL 138738A0 IL 13873899 A IL13873899 A IL 13873899A IL 13873899 A IL13873899 A IL 13873899A IL 138738 A0 IL138738 A0 IL 138738A0
Authority
IL
Israel
Prior art keywords
substituted pyrrolidine
metalloprotease inhibitors
hydroxamate metalloprotease
pyrrolidine hydroxamate
inhibitors
Prior art date
Application number
IL13873899A
Other languages
English (en)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of IL138738A0 publication Critical patent/IL138738A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
IL13873899A 1998-04-14 1999-04-09 Substituted pyrrolidine hydroxamate metalloprotease inhibitors IL138738A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8166798P 1998-04-14 1998-04-14
PCT/US1999/007826 WO1999052868A1 (en) 1998-04-14 1999-04-09 Substituted pyrrolidine hydroxamate metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
IL138738A0 true IL138738A0 (en) 2001-10-31

Family

ID=22165611

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13873899A IL138738A0 (en) 1998-04-14 1999-04-09 Substituted pyrrolidine hydroxamate metalloprotease inhibitors

Country Status (21)

Country Link
US (1) US6329418B1 (xx)
EP (1) EP1073635A1 (xx)
JP (1) JP2002511448A (xx)
KR (1) KR100400507B1 (xx)
CN (1) CN1297436A (xx)
AR (1) AR029145A1 (xx)
AU (1) AU753048B2 (xx)
BR (1) BR9909620A (xx)
CA (1) CA2328211A1 (xx)
CO (1) CO5011039A1 (xx)
HU (1) HUP0102195A3 (xx)
ID (1) ID26925A (xx)
IL (1) IL138738A0 (xx)
NO (1) NO20005196L (xx)
NZ (1) NZ507076A (xx)
PE (1) PE20000425A1 (xx)
PL (1) PL343529A1 (xx)
SK (1) SK15462000A3 (xx)
TR (1) TR200002971T2 (xx)
WO (1) WO1999052868A1 (xx)
ZA (1) ZA200005047B (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403632B1 (en) * 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
EP1268418B1 (en) 2000-03-27 2006-06-14 Applied Research Systems ARS Holding N.V. Pharmaceutically active pyrrolidine derivatives as bax inhibitors
WO2001072705A1 (en) 2000-03-27 2001-10-04 Applied Research Systems Ars Holding N.V. Pharmaceutically active pyrrolidine derivatives as bax inhibitors
US8283135B2 (en) 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
MXPA03000504A (es) 2000-07-19 2003-06-24 Hoffmann La Roche Derivados de pirimidina.
FR2819252A1 (fr) * 2001-01-11 2002-07-12 Servier Lab Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
ES2303854T3 (es) * 2001-03-20 2008-09-01 Laboratoires Serono Sa Derivados de ester de pirrolidina con actividad moduladora de oxitocina.
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
UA78058C2 (en) * 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
CN1294120C (zh) * 2003-10-21 2007-01-10 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其应用
KR20060124775A (ko) * 2004-02-26 2006-12-05 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 피롤리딘 옥심의 제조방법
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
WO2006038265A1 (ja) * 2004-09-30 2006-04-13 Yutaka Imauchi 耳硬化症治療のための医薬組成物
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
AR077214A1 (es) 2009-06-24 2011-08-10 Neurocrine Biosciences Inc Heterociclos nitrogenados y composiciones farmaceuticas que los contienen
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
UA122210C2 (uk) 2014-07-02 2020-10-12 Обсева С.А. Кристалічний о-метилоксим (3z,5s)-5-(гідроксиметил)-1-[(2'-метил-1,1'-біфеніл-4-іл)карбоніл]піролідин-3-oну, корисний у способах лікування станів, пов'язаних з активністю ot-r

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3380992A (en) * 1965-06-14 1968-04-30 Upjohn Co Lincomycin derivatives and process for preparing same
US4377701A (en) * 1981-09-21 1983-03-22 E. R. Squibb & Sons, Inc. 4-Methylene-1-[[(alranoyl or arylcarbonyl)mercapto]acyl]proline and pipecolic acid
US4743587A (en) 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4771038A (en) 1986-01-21 1988-09-13 Ici Americas Inc. Hydroxamic acids
DK77487A (da) 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
ZW23187A1 (en) 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
US5183900A (en) 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
GB9102635D0 (en) 1991-02-07 1991-03-27 British Bio Technology Compounds
GB9107368D0 (en) 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
AU2228292A (en) 1991-06-14 1993-01-12 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
JPH05125029A (ja) 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
JPH07503016A (ja) 1992-01-15 1995-03-30 メルク　エンド　カンパニー　インコーポレーテッド 変形防止剤としての置換されたホスフィン酸含有ペプチジル誘導体
EP1002556A3 (en) 1992-05-01 2001-01-10 British Biotech Pharmaceuticals Limited Use of MMP inhibitors
US5318964A (en) 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
AU666727B2 (en) 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
ATE182137T1 (de) 1993-04-27 1999-07-15 Celltech Therapeutics Ltd Peptidylderivate als inhibitoren von metalloproteinase
GB9308695D0 (en) 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
DE69415159T2 (de) 1993-08-02 1999-07-22 Celltech Therapeutics Ltd., Slough, Berkshire Succinamid-derivate, verfahren zu ihrer herstellung und ihre verwendung als gelatinase- und collagenase- inhibitoren
GB9316162D0 (en) * 1993-08-04 1993-09-22 Zeneca Ltd Fungicides
US5545735A (en) 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone
US5470834A (en) 1993-10-06 1995-11-28 Florida State University Sulfoximine and suldodiimine matrix metalloproteinase inhibitors
US5403952A (en) 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
UA48121C2 (uk) 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
GB9323165D0 (en) 1993-11-10 1994-01-05 Chiros Ltd Compounds
BR9506535A (pt) 1994-01-20 1997-09-16 British Biotech Pharm Inibidores de metaloproteinases
GB9401129D0 (en) 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
ES2139183T3 (es) 1994-01-22 2000-02-01 British Biotech Pharm Inhibidores de las metaloproteinasas.
US5514716A (en) 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
GB9404046D0 (en) 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
GB9405076D0 (en) 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
DE4411311A1 (de) 1994-03-31 1995-10-05 Basf Ag Verfahren zur Herstellung von lagerstabilen wäßrigen Lösungen von Vinylamin-Einheiten enthaltenden Polymerisaten
GB9501737D0 (en) 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
WO1995029892A1 (en) 1994-04-28 1995-11-09 The Du Pont Merck Pharmaceutical Company Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
JPH07304770A (ja) 1994-05-11 1995-11-21 Kanebo Ltd 新規ベンゾアゼピノン誘導体
US6028110A (en) 1994-05-28 2000-02-22 British Biotech Pharmaceuticals Ltd. Succinyl hydroxamic acid, N-formyl-N-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
GB9411088D0 (en) 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
GB9411598D0 (en) 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
GB9412350D0 (en) 1994-06-20 1994-08-10 Fujisawa Pharmaceutical Co New compound and its preparation
CN1151157A (zh) 1994-06-22 1997-06-04 英国生物技术药物有限公司 金属蛋白酶抑制剂
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
GEP20012388B (en) 1995-12-08 2001-03-25 Agouron Pharma Metalloproteinase Inhibitors, Pharmaceutical Compositions on Their Base, Use and Methods for Obtaining and Intermediates
WO1998008815A1 (en) 1996-08-28 1998-03-05 The Procter & Gamble Company Substituted cyclic amine metalloprotease inhibitors

Also Published As

Publication number Publication date
CA2328211A1 (en) 1999-10-21
PE20000425A1 (es) 2000-07-13
ID26925A (id) 2001-02-22
SK15462000A3 (sk) 2001-06-11
PL343529A1 (en) 2001-08-27
NO20005196D0 (no) 2000-10-16
WO1999052868A1 (en) 1999-10-21
TR200002971T2 (tr) 2001-02-21
AU3552299A (en) 1999-11-01
AU753048B2 (en) 2002-10-03
EP1073635A1 (en) 2001-02-07
US6329418B1 (en) 2001-12-11
JP2002511448A (ja) 2002-04-16
CN1297436A (zh) 2001-05-30
HUP0102195A2 (hu) 2001-11-28
HUP0102195A3 (en) 2001-12-28
NZ507076A (en) 2003-04-29
KR20010042694A (ko) 2001-05-25
AR029145A1 (es) 2003-06-18
NO20005196L (no) 2000-12-14
CO5011039A1 (es) 2001-02-28
ZA200005047B (en) 2001-06-06
BR9909620A (pt) 2000-12-19
KR100400507B1 (ko) 2003-10-08

Similar Documents

Publication Publication Date Title
PL343529A1 (en) Substituted pyrrolidine hydroxamate metalloprotease inhibitors
GB9912961D0 (en) Metalloprotease inhibitors
EP1124822A4 (en) THROMBIN INHIBITORS
PL349192A1 (en) Protease inhibitors
IL128662A0 (en) Heterocyclic metalloprotease inhibitors
IL128664A0 (en) Heterocyclic metalloprotease inhibitors
HUP0004595A3 (en) Acyclic metalloprotease inhibitors
IL135289A0 (en) Novel lactam metalloprotease inhibitors
HK1049660A1 (en) Sulfamato hydroxamic acid metalloprotease inhibitor
EP1093367A4 (en) PROTEASE INHIBITORS
IL128665A0 (en) Bidenatate metalloprotease inhibitors
IL145085A0 (en) Dihetero-substituted metalloprotease inhibitors
EP1117660A4 (en) THROMBIN INHIBITORS
IL136139A0 (en) Thrombin inhibitors
EP1067894A4 (en) PROTHEASEINHIBITOREN
IL136889A0 (en) Matrix metalloprotease inhibitors
EP1079821A4 (en) PROTEASE INHIBITORS
EP1140897A4 (en) PROTEASE INHIBITORS
EP1086083A4 (en) PROTEASE INHIBITORS
GB9415619D0 (en) Metalloprotease inhibitors
SI1181017T1 (en) Metalloprotease inhibitors
AU6843598A (en) Metalloproteinase inhibitors
GB9809784D0 (en) Thrombin Inhibitors
GB9807941D0 (en) Thrombin inhibitors
GB9806034D0 (en) Thrombin inhibitors